Elutia

ELUT · NASDAQ

$0.8105−$0.0047 (−0.58%)TodayMarket closed · Oct 20, 4:00 PM ET

Prev close $0.8152

Latest news

Press releaseOct 1, 4:45 PM ETGlobe Newswire
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
Press releaseAug 18, 8:00 AM ETGlobe Newswire
Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch
NewsAug 13, 6:00 PM ET
Elutia Q2 2026 Earnings Call Transcript
Press releaseAug 13, 4:10 PM ETGlobe Newswire
Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results
Press releaseAug 13, 4:05 PM ETGlobe Newswire
Elutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery Market
NewsJul 17, 12:07 PM ETVandana Singh
Elutia Sheds Legacy Business to Chase $1.5 Billion Market Opportunity
Press releaseMay 22, 10:09 AM ETGlobe Newswire
A Reno Biotech Just Rang the Nasdaq Bell — Here's Why the Whole Regenerative-Medicine Tape Is Worth Watching
NewsMay 14, 5:55 PM ET
Elutia Reports Q1 2026 Results: Full Earnings Call Transcript
Press releaseMay 14, 4:05 PM ETGlobe Newswire
Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market
NewsMay 14, 7:11 AM ET
Earnings Scheduled For May 14, 2026
Press releaseMar 11, 4:05 PM ETGlobe Newswire
Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process
NewsMar 11, 7:11 AM ET
Earnings Scheduled For March 11, 2026
NewsMar 10, 2:01 PM ET
Exploring Elutia's Earnings Expectations
NewsNov 6, 6:12 AM ET
Earnings Scheduled For November 6, 2025
NewsAug 14, 5:06 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
NewsMay 8, 4:33 AM ET
Earnings Scheduled For May 8, 2025
Press releaseOct 17, 4:15 PM ETACCESSWIRE
SWK Holdings Provides Portfolio Update

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029

Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch

Elutia Q2 2026 Earnings Call Transcript

Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results

Elutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery Market

Elutia Sheds Legacy Business to Chase $1.5 Billion Market Opportunity

A Reno Biotech Just Rang the Nasdaq Bell — Here's Why the Whole Regenerative-Medicine Tape Is Worth Watching

Elutia Reports Q1 2026 Results: Full Earnings Call Transcript

Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market

Earnings Scheduled For May 14, 2026

Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process

Earnings Scheduled For March 11, 2026

Exploring Elutia's Earnings Expectations

Earnings Scheduled For November 6, 2025

12 Health Care Stocks Moving In Thursday's After-Market Session

Earnings Scheduled For May 8, 2025

SWK Holdings Provides Portfolio Update